BitMart has appointed Alvarez & Marsal as its financial adviser to assess its financial position, stakeholder claims, and withdrawal arrangements following a trading halt announced on August 26. The exchange is reviewing possible paths including an orderly wind-down, phased restart, or third-party proposals but has not provided audited asset figures or a repayment schedule. BitMart plans to launch a user feedback portal within five business days and aims to announce an action plan within three weeks. Until then, key details on asset status, withdrawal timelines, and creditor recoveries remain unclear, leaving users uncertain about their funds and the exchange’s future.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
